While the marketing application in Europe remains under review, U.S. regulators' complete response letter (CRL) to Biomarin Pharmaceutical Inc. for Kyndrisa (drisapersen) in Duchenne muscular dystrophy (DMD) hardly stirred company backers, given the negative advisory committee (adcom) meeting in November.